Verona Pharma Statistics
Total Valuation
Verona Pharma has a market cap or net worth of $3.44 billion. The enterprise value is $3.22 billion.
Important Dates
The last earnings date was Monday, November 4, 2024, before market open.
Earnings Date | Nov 4, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Verona Pharma has 81.83 million shares outstanding. The number of shares has increased by 3.55% in one year.
Current Share Class | n/a |
Shares Outstanding | 81.83M |
Shares Change (YoY) | +3.55% |
Shares Change (QoQ) | +0.57% |
Owned by Insiders (%) | 4.10% |
Owned by Institutions (%) | 63.88% |
Float | 50.15M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | 25.99 |
PB Ratio | 26.35 |
P/TBV Ratio | 26.46 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 573.40 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.03, with a Debt / Equity ratio of 0.94.
Current Ratio | 13.03 |
Quick Ratio | 12.47 |
Debt / Equity | 0.94 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -10.93 |
Financial Efficiency
Return on equity (ROE) is -78.03% and return on invested capital (ROIC) is -35.24%.
Return on Equity (ROE) | -78.03% |
Return on Assets (ROA) | -28.05% |
Return on Capital (ROIC) | -35.24% |
Revenue Per Employee | $71,190 |
Profits Per Employee | -$1.95M |
Employee Count | 79 |
Asset Turnover | 0.02 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Verona Pharma has paid $1.97 million in taxes.
Income Tax | 1.97M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +140.39% in the last 52 weeks. The beta is 0.43, so Verona Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.43 |
52-Week Price Change | +140.39% |
50-Day Moving Average | 37.57 |
200-Day Moving Average | 24.30 |
Relative Strength Index (RSI) | 60.87 |
Average Volume (20 Days) | 938,322 |
Short Selling Information
Short Interest | 6.36M |
Short Previous Month | 5.98M |
Short % of Shares Out | 8.11% |
Short % of Float | n/a |
Short Ratio (days to cover) | 5.44 |
Income Statement
In the last 12 months, Verona Pharma had revenue of $5.62 million and -$153.72 million in losses. Loss per share was -$1.93.
Revenue | 5.62M |
Gross Profit | 5.08M |
Operating Income | -151.30M |
Pretax Income | -123.69M |
Net Income | -153.72M |
EBITDA | -150.30M |
EBIT | -151.30M |
Loss Per Share | -$1.93 |
Full Income Statement Balance Sheet
The company has $336.04 million in cash and $122.31 million in debt, giving a net cash position of $213.73 million or $2.61 per share.
Cash & Cash Equivalents | 336.04M |
Total Debt | 122.31M |
Net Cash | 213.73M |
Net Cash Per Share | $2.61 |
Equity (Book Value) | 130.49M |
Book Value Per Share | 1.59 |
Working Capital | 336.30M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$103.77 million and capital expenditures -$45,000, giving a free cash flow of -$103.81 million.
Operating Cash Flow | -103.77M |
Capital Expenditures | -45,000 |
Free Cash Flow | -103.81M |
FCF Per Share | -$1.27 |
Full Cash Flow Statement Margins
Gross Margin | 90.34% |
Operating Margin | -2,690.33% |
Pretax Margin | -2,698.40% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Verona Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -3.55% |
Shareholder Yield | -3.55% |
Earnings Yield | -4.47% |
FCF Yield | -3.02% |
Dividend Details Analyst Forecast
The average price target for Verona Pharma is $43.83, which is 4.31% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $43.83 |
Price Target Difference | 4.31% |
Analyst Consensus | Strong Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Verona Pharma has an Altman Z-Score of 1.36 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.36 |
Piotroski F-Score | 3 |